🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 888314606 (prev. 888314507 )
- Market Cap
- Micro Cap · $40 Million
- Previous Symbol
- TTP (changed 12/24/2008)
Business: Titan Pharmaceuticals, Inc. is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate is Probuphine, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.
Notes: November 30, 2020, following receipt of stockholder approval, the Company amended its certificate of incorporation to effect a 1-for-30 reverse split of its common stock. The shares began trading on a post-split basis on December 1, 2020 and have closed above the $1.00 minimum bid price since such date. Immediately after the reverse split becomes effective, there will be approximately 6.6 million shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 888314606, effective December 1, 2020, and continue to trade under the symbol "TTNP." All stock options and warrants of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted.
Company Contact
- CHR
- Marc Rubin
- CFO
- Sunil Bhonsle
- Headquarters
- 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
- Phone
- 650-244-4990
- Fax
- 650-244-4956
- Investor Relations
- Stephen Kilmer · 650-989-2215 · skilmer@titanpharm.com